February 23, 2017 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results HERCULES, Calif.–February 23, 2017–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financia
January 16, 2017 Dear Valued Customers and Distributor Partners, Today Bio-Rad Laboratories, Inc. has announced the signing of a definitive agreement to acquire RainDance Technologies, Inc. Please reference the press release. The transaction is subject to the approval of shareholders,
Next Gen Dx Summit Booth #28 August 23-26, 2016 Washington, DC www.nextgenerationdx.com Circulating Tumor Cell Program: Wed., August 24th at 12:50pm (Lunch Provided) Sensitive Assays to Detect Mutant ESR1 in Plasma Circulating Tumor DNA from Breast Cancer Patient Samples
Abstract: Library preparation methods are the backbone of any next-generation sequencing (NGS) assay. RainDance Technologies’ patented picoliter droplet technology ensures single DNA molecule occupancy during multiplex droplet PCR targeted enrichment to generate NGS libraries with sup
Abstract The BCR-ABL1 fusion gene sequence is used to help diagnose and monitor treatment and recurrence for chronic myelogenous leukemia (CML). In fact, between 90-95% of diagnosed CML cases are BCR-ABL1-positive. While reverse transcription quantitative PCR (RT-qPCR) is the gold sta
RainDance Technologies prides itself on its continued innovation and ability to deliver Digital Droplet-based solutions that fundamentally enhance the way researchers and scientists study cell-based and cell-free biomarkers in cancer, infectious disease and inherited disorders. We are
The HudsonAlpha Institute for Biotechnology has been named the latest RainDance Center of Excellence and is now a premier reference site and service provider for RainDance products. HudsonAlpha is a nonprofit research institute committed to improving human health and the quality of li
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.